Verici Dx plc (LON:VRCI – Get Free Report)’s stock price traded down 16.9% during trading on Friday . The stock traded as low as GBX 5.20 ($0.07) and last traded at GBX 5.40 ($0.07). 236,310 shares changed hands during trading, a decline of 24% from the average session volume of 311,211 shares. The stock had previously closed at GBX 6.50 ($0.09).
Verici Dx Stock Down 15.4 %
The stock has a market cap of £13.34 million, a price-to-earnings ratio of -275.00 and a beta of 1.59. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The stock’s 50-day moving average price is GBX 6.75 and its 200-day moving average price is GBX 7.22.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Recommended Stories
- Five stocks we like better than Verici Dx
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- When to Sell a Stock for Profit or Loss
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
